PMC3700468_01
Pathological findings of the primary resected specimen showing invasive ductal carcinoma, papillotubular carcinoma with scirrhous carcinoma (A x40). Tumor cells are positive for estrogen receptor (B x100).
amjcaserep-14-184-g001.jpg
PMC3700468_01_amjcaserep-14-184-g001.jpg
f1-amjcaserep-14-184
Pathological examination of the primary specimen revealed 25x25 mm in size, invasive ductal carcinoma with metastasis to the axillary lymph node, and estrogen and progesterone receptor positivity (Figure 1).
Chest CT scan showing bilateral and right massive pleural effusion.
amjcaserep-14-184-g002.jpg
PMC3700468_01_amjcaserep-14-184-g002.jpg
f2-amjcaserep-14-184
Chest X-ray and computed tomography showed bilateral pleural effusion, predominantly on the right side (Figure 2).
Immunocytological examinations of the thoracentesis fluid revealing estrogen receptor-positive adenocarcinoma cells.
amjcaserep-14-184-g003.jpg
PMC3700468_01_amjcaserep-14-184-g003.jpg
f3-amjcaserep-14-184
Immunohistochemical analysis revealed that the tumor cells were positive for estrogen receptor and progesterone receptor (Figure 3).
Chest X-ray film taken 3 months after starting oral hormonal therapy showing disappearance of bilateral pleural effusion.
amjcaserep-14-184-g004.jpg
PMC3700468_01_amjcaserep-14-184-g004.jpg
f4-amjcaserep-14-184
The pleural effusion had disappeared 3 months later (Figure 4).
Re-accumulation of pleural fluid is not observed 8 months after the start of treatment.
amjcaserep-14-184-g005.jpg
PMC3700468_01_amjcaserep-14-184-g005.jpg
f5-amjcaserep-14-184
Chest X-ray demonstrated that the pleural effusion remained absent at 8 months after the start of treatment (Figure 5).